Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for tumor immunotherapy

A drug and tumor technology, applied in the field of drug combination of tumor immunotherapy, can solve the problem of patients unable to respond to immunotherapy

Active Publication Date: 2020-10-30
XIAMEN UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tumor immunotherapy, as a new type of cancer treatment, has a significant effect on some patients. Unfortunately, most patients cannot respond to immunotherapy alone clinically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for tumor immunotherapy
  • Pharmaceutical composition for tumor immunotherapy
  • Pharmaceutical composition for tumor immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] 1.[ 18 F] Synthesis of FDG

[0058] [ 18 F] FDG was synthesized by the IBA automation module. Based on the premise of trifluoromannose, the method of alkali hydrolysis chemical synthesis. Step 1 is the nucleophilic fluorination reaction: the cyclotron produces [ 18 F]F - , under helium transport, [ 18 F]F - Adsorbed onto the QMASep-Pak anion exchange column, under the action of a vacuum pump, take a mixture of potassium carbonate (6mg / mL) dissolved in water and phase transfer catalyst K2.2.2 (20mg / mL) dissolved in acetonitrile ,Will[ 18 F]F - Eluted into the reaction vial. [ 18 F]F - The nucleophilic activity of ions is one of the key factors affecting the reaction yield, so it is very important to remove water in the reaction system. Dry [ 18 F]F - , catalyst amino polyether (K2.2.2) to chelate potassium ions in the system, so that [ 18 F]F - It is exposed to increase its nucleophilic activity (activation of fluoride ions), followed by a nucleophilic fl...

Embodiment 2

[0066] The following is the determination of the impact of different nuclides on the expression of PD-L1 and the markers synthesized by the method of the above-mentioned Example 1[ 18 F]FDG and 99m Description of the distribution and therapeutic effect of Tc-RGD in vivo:

[0067] 1. Flow cytometry to detect the effect of different nuclides on the expression of PD-L1

[0068] CT26, MC38, 4T1 and B16F10 tumor cells were plated in six-well plates overnight, and 740kBq of radionuclide Na was added to each well 18 F, The cells of the control group were added with an equal volume of normal saline, and the cells of the experimental group and the control group were cultured in different incubators to ensure that the control group was not affected. After incubation at different time points (0.5h, 2h, 4h, 8h and 24h), the cells were collected and washed twice with ice-cold PBS, then stained with anti-PD-L1 antibody (abcam, ab238697), and restained overnight Fluorescent secondary anti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for tumor immunotherapy, and provides a new application of radionuclide or a marker thereof, and the new application is an application of the radionuclide or the marker thereof in remodeling a tumor immunological microenvironment. The invention also provides a pharmaceutical composition for tumor immunotherapy of a human body or a mouse. The pharmaceutical composition is prepared from radionuclide or the marker thereof and an immune checkpoint inhibitor according to a specific ratio. The invention also provides a kit for tumor immunotherapy. The kit contains the pharmaceutical composition for tumor immunotherapy of human bodies or mice. According to the pharmaceutical composition provided by the invention, the tumor immune microenvironment can be remodeled while the tumor is detected through radionuclide or the marker thereof, so that the tumor growth speed is remarkably reduced through the immune checkpoint inhibitor, and the lifetime is prolonged. The pharmaceutical composition disclosed by the invention has a good synergistic effect, and the kit disclosed by the invention is convenient to use and easy to realize clinical popularization.

Description

technical field [0001] The invention belongs to the field of chemical drugs, in particular to a drug combination for tumor immunotherapy. Background technique [0002] In recent years, malignant tumors have become one of the major public health problems that seriously threaten human health. In my country, the incidence and mortality of cancer rank first in the world! Therefore, it is still an arduous task to reduce the incidence and mortality of malignant tumors in my country. [0003] A large number of clinical practices have proved that the combination of early diagnosis and early treatment can reduce the mortality of cancer patients and significantly prolong the life span of cancer patients. Early malignant tumors usually lack obvious clinical signs, and imaging examination is the main means of early diagnosis. High-resolution molecular imaging techniques PET and SPECT combined with highly sensitive and highly specific radionuclide-labeled probes are expected to reflec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/04A61K51/08A61K45/06A61K39/395A61P35/00A61K101/02A61K103/10
CPCA61K51/0491A61K51/082A61K45/06A61K39/39558A61P35/00A61K2300/00
Inventor 张现忠文雪君郭志德石昌荣曾馨莹
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com